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Question 2. Roughly how many deaths occur each year as a result of severe falciparum malaria?
100,000-500,000 1-3 million
3-5 million
Question 3. For uncomplicated falciparum malaria, which of the following best refl ects the evidence on empirical treatment (i.e., giving antimalarial drugs to all people with fever without confi rming the disease) in stable endemic areas?
There is good evidence from randomized controlled trials (RCTs) that empirical treatment is more clinically effective and cost effective than treating only cases confi rmed by microscopy or rapid diagnostic tests There is good evidence from RCTs that empirical treatment is less clinically effective and less cost-effective than treating only cases confi rmed by microscopy or rapid diagnostic tests There have been no RCTs comparing these two approaches
Question 4. Which of the following is true about artemisinin-based combination therapy?
Artemisinin-based combination therapy (ACT) is more expensive than chloroquine by a factor of 10-20
In Africa, there are high rates of falciparum resistance to artemisinin derivatives The WHO does not recommend ACT as a fi rst-line treatment for falciparum malaria Question 5. Which of the following best refl ects the evidence on adding artesunate to amodiaquine, rather than using amodiaquine alone, for treating uncomplicated falciparum malaria?
The combination treatment is associated with a lower rate of parasitological failure (parasitemia detected within a specifi c time after treatment), but it does not reduce gametocytemia (microscopic evidence of gametes in the blood) compared with amodiaquine alone
The combination treatment is associated with a lower rate of parasitological failure and with a lower rate of gametocytemia
The combination therapy is associated with a signifi cantly higher rate of adverse events Question 6. Which one of the following best refl ects the evidence on using artesunate plus SP for treating uncomplicated falciparum malaria?
There is very good evidence that this combination is more effective than SP alone, and that it is more effective than amodiaquine plus SP There is no good evidence that artesunate plus SP is more effective than SP alone There is very good evidence that artesunate plus SP is more effective than SP alone, but there is little evidence that artesunate plus SP is more effective than amodiaquine plus SP Question 7. Which of the following best refl ects the evidence on ACT for treating uncomplicated falciparum malaria?
Six doses of artemether-lumefantrine given over three days increases treatment cure rates compared with a four-dose regime Artesunate plus chlorproguanil-dapsone is more effective than artemether-lumefantrine Artemether-lumefantrine is more effective than artesunate-mefl oquine Question 8. The WHO recommends that countries use a combination of drugs to treat falciparum malaria once resistance to monotherapies has exceeded which of the following levels? Question 9. Which of the following is true about global ACT supply and demand?
There is a wide variety of different ACTs available for use by countries as a coformulated blister pack
The WHO estimates that at least 132 million courses of ACT will be needed in 2005
Although artemisinin compounds are derived from a raw substance extracted from the plant Artemisia annua, a synthetic version is now available for clinical use Question 10. Which of the following best refl ects the evidence on using artemether for treating severe, life-threatening falciparum malaria in nonpregnant patients?
Death rates are higher with artemether than with quinine Death rates are higher with quinine than with artemether Artemether is associated with faster speed of recovery from coma and fever clearance time, and a lower rate of neurological sequelae, than quinine There is no signifi cant difference in death rates between artemether and quinine Answer 1. 500 million Robert Snow and colleagues recently estimated that there were 515 million episodes of clinical P. falciparum malaria in 2002 (range 300-660 million) [1] .
Answer 2. 1-3 million
A World Health Organization (WHO) expert committee estimated that there are 1.1-2.7 million deaths each year due to severe falciparum malaria (http:⁄⁄mosquito.who.int/docs/ ecr20_toc.htm).
Answer 3. There have been no RCTs comparing these two approaches
In their systematic review of the literature, Taylor-Robinson and colleagues found no RCTs comparing empirical treatment with treatment of confi rmed malaria [1] . The authors pointed out that (1) such empirical treatment used to be common; (2) newer malaria treatments are more expensive, and, therefore, empirical treatment is being questioned; (3) testing everyone will, however, be costly; and (4) treating only people who test positive might delay treatment, and people may default before test results are obtained [1] .
Answer 4. ACT is more expensive than chloroquine by a factor of 10-20
Treating an adult with chloroquine costs about ten cents [1] . Snow and colleagues calculated the cost of ACT as follows: $1.20 for an adult dose of artesunate plus sulfadoxine-pyrimethamine ([SP]; sulfadoxine, 25 milligrams/kilograms of body weight over a one-day period; pyrimethamine, 12.5 milligrams/kilograms of body weight over a one-day period; artesunate, 4 milligrams/kilograms of body weight over a three-day period); $1.30 for an adult dose of artesunate plus amodiaquine (amodiaquine, 25 milligrams/kilograms of body weight over a three-day period; artesunate, 4 milligrams/kilograms of body weight over a three-day period); and $2.40 for an adult dose of artemether-lumefantrine (lumefantrine, 48 milligrams/ kilograms of body weight over a three-day period; artemether, 8 milligrams/kilograms of body weight over a three-day period) [2] . The WHO states that to date there has been no documented falciparum resistance to artemisinin derivatives [3] . The WHO offi cially includes ACT as a fi rst-line option for treatment [4] . The organization states that as of 25 October 2005, 53 countries (35 in Africa) have now adopted ACT as fi rst-line treatment [3] .
Answer 5. The combination treatment is associated with a lower rate of parasitological failure and with a lower rate of gametocytemia A systematic review by Adjuik et al. found lower rates of parasitological failure at day 28 and gametocytemia at day 7 with a three-day course of artesunate plus amodiaquine compared with amodiaquine alone [1] . The review found no signifi cant difference in the rate of serious adverse events between treatments. Answer 6. There is very good evidence that artesunate plus SP is more effective than SP alone, but there is little evidence that artesunate plus SP is more effective than amodiaquine plus SP The systematic review by Adjuik et al. found that artesunate plus SP reduced the parasitological failure at day 28 and the gametocytemia rate at day 7 compared with SP alone [1] . When Taylor-Robinson and colleagues systematically reviewed the evidence on artesunate plus SP compared with amodiaquine plus SP, they found only one RCT [2] , showing that there was no signifi cant difference in treatment failure rates at day 28.
Answer 7. Six doses of artemether-lumefantrine given over three days increases treatment cure rates compared with a four-dose regime One RCT found that six doses of artemether-lumefantrine given over three days increases treatment cure rates compared with a four-dose regime [1] .
There have been no trials yet of artesunate plus chlorproguanil-dapsone versus artemether-lumefantrine, while artemether-lumefantrine is probably no more effective than artesunate-mefl oquine, although the data are not yet clear (Paul Garner, personal communication).
Answer 9. The WHO estimates that at least 132 million courses of ACT will be needed in 2005
The WHO estimates that a minimum of 132 million courses of ACT will be needed in 2005 [1] . There is only one coformulated ACT, which is artemetherlumefantrine (Coartem) [1] . WHO and Novartis, the manufacturer of artemether-lumefantrine, have entered into a special pricing agreement: Novartis provides the drug at cost price ($ 0.9 and $ 2.4 per child and adult treatment course, respectively) for use in the public sector in malariaendemic countries [1] . Although researchers are in the process of developing a synthetic version of artemisinin (for example, the Gates Foundation has given a $43 million grant to United States researchers for such development [http:⁄⁄www.berkeley.edu/ news/media/releases/2004/12/13_gates.shtml]), this synthetic version is not yet clinically available.
Answer 10. There is no signifi cant difference in death rates between artemether and quinine
There is good evidence (from two systematic reviews [1, 2] and four subsequent RCTs [3] [4] [5] [6] ) that there is no signifi cant difference in death rates between artemether and quinine in people with severe malaria. One of the reviews [1] found no signifi cant difference in speed of recovery from coma, fever clearance time, or rate of neurological sequelae.
